Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10409914 | 0.96 | LMNA (0.36) | LMNAGRIN1GRIN2ASLC22A1GRIN2D | |
| SCHEMBL20198595 | 0.85 | — | — | |
| SCHEMBL12757988 | 0.79 | — | — | |
| SCHEMBL9815660 | 0.78 | — | — | |
| SCHEMBL1903771 | 0.78 | PNMT (0.40) | LMNAGRIN1GRIN2ASLC22A1GRIN2D | |
| Hydrochloric Acid SCHEMBL2875147 | 0.74 | PNMT (0.38) | LMNAPNMTPMP22 | |
| SCHEMBL9951831 | 0.70 | LMNA (0.36) | LMNAGRIN1GRIN2ASLC22A1GRIN2D | |
| SCHEMBL19850684 | 0.67 | PNMT (0.35) | PNMT | |
| SCHEMBL22842441 | 0.67 | LMNA (0.32) | LMNAGRIN1GRIN2ASLC22A1GRIN2D | |
| SCHEMBL71836 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787814-B2 | Method for preparing 2-indolinospirone compound and intermediate thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-10-17 | — | — | US | disclosed |
| US-11649224-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| WO-2019075004-A1 | SYNTHESIS OF BICYCLO[2.2.2]OCTANE DERIVATIVES | EASTMAN CHEMICAL COMPANY (US) | 2019-04-18 | — | — | WO | disclosed |
| US-9944666-B2 | Compounds that are S1P modulating agents and/or ATX modulating agents | BIOGEN MA INC. (US) | 2018-04-17 | — | — | US | disclosed |
| EP-3271334-A1 | SUBSTITUTED N-BICYCLO-2-ARYL-QUINOLIN-4-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2018-01-24 | — | — | EP | disclosed |
| US-9650573-B2 | Liquid crystalline medium and liquid crystal device | MERCK PATENT GMBH (DE) | 2017-05-16 | — | — | US | disclosed |
| WO-2016146602-A1 | SUBSTITUTED N-BICYCLO-2-ARYL-QUINOLIN-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-22 | — | — | WO | disclosed |
| US-20160108318-A1 | LIQUID CRYSTALLINE MEDIUM AND LIQUID CRYSTAL DEVICE | MERCK PATENT GMBH (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160060530-A1 | DEVICE CONTAINING A LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2016-03-03 | — | — | US | disclosed |
| US-7435833-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2008-10-14 | — | — | US | disclosed |
| WO-2008100423-A1 | GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008063714-A1 | METABOLICALLY-STABILIZED INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2008-05-29 | — | — | WO | disclosed |
| US-20080119549-A1 | METABOLICALLY-STABILIZED INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2008-05-22 | — | — | US | disclosed |
| US-20080076819-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-03-27 | — | — | US | disclosed |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | AMGEN INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007118185-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070167501-A1 | Bicyclo derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1719757-A1 | BICYCLO DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-0107801-B1 | PROCESS FOR ELECTROLESS PLATING OF METAL SURFACES WITH LAYERS OF METAL | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1987-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076819-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD11B2, HSD17B1 | LMNA 3653/4885GRIN1 324/4885GRIN2A 929/4885 |
| US-20080119549-A1 | METABOLICALLY-STABILIZED INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ABHD6 | LMNA 4058/4885GRIN1 2877/4885GRIN2A 2768/4885 |
| US-11787814-B2 | Method for preparing 2-indolinospirone compound and intermediate thereof | CYP51A1, CYP11B2, CYP3A5 | LMNA 1424/4885GRIN1 3413/4885GRIN2A 2326/4885 |
| US-20070167501-A1 | Bicyclo derivative | DPP4, DPP7, DPP9 | LMNA 4789/4885GRIN1 284/4885GRIN2A 708/4885 |
| US-11649224-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | LMNA 2127/4885GRIN1 4736/4885GRIN2A 4756/4885 |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | HSD11B1, HSD3B1, HSD17B1 | LMNA 2340/4885GRIN1 475/4885GRIN2A 2054/4885 |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | LMNA 1018/4885GRIN1 408/4885GRIN2A 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.